Disorders of cobalamin (vitamin B 12 ) metabolism are increasingly recognized in small animal medicine and have a variety of causes ranging from chronic gastrointestinal disease to hereditary defects in cobalamin metabolism. Measurement of serum cobalamin concentration, often in combination with serum folate concentration, is routinely performed as a diagnostic test in clinical practice. While the detection of hypocobalaminemia has therapeutic implications, interpretation of cobalamin status in dogs can be challenging. The aim of this review is to define hypocobalaminemia and cobalamin deficiency, normocobalaminemia, and hypercobalaminemia in dogs, describe known cobalamin deficiency states, breed predispositions in dogs, discuss the different biomarkers of importance for evaluating cobalamin status in dogs, and discuss the management of dogs with hypocobalaminemia. K E Y W O R D S cobalamin deficiency, cubam receptor, folate, homocysteine, hypercobalaminemia, hypocobalaminemia, methylmalonic acid, vitamin B 12
The aim of this review is to critically evaluate the veterinary literature to define serum cobalamin status (normocobalaminemia, hypocobalaminemia and cobalamin deficiency, and hypercobalaminemia), describe causes of cobalamin deficiency states in dogs including breed predispositions, summarize breed-specific changes in cobalamin metabolism, discuss biomarkers of importance for evaluating cobalamin status in dogs, and discuss the treatment options for dogs in which a suboptimal or deficient cobalamin status has been diagnosed.
| COBALAMIN METABOLISM IN DOGS

| Ingestion and absorption of cobalamin
Cobalamin is a water-soluble vitamin, also referred to as vitamin B 12 .
It is mainly ingested with food of animal origin with liver, kidney, meat, Abbreviations: AMN, amnionless; CIE, chronic inflammatory enteropathies; CUBN, cubilin; EPI, exocrine pancreatic insufficiency; GC/MS, gas chromatography-mass spectrometry; GI, gastrointestinal; HCY, homocysteine; IBD, inflammatory bowel disease; IF, intrinsic factor; IGS, Imerslund-Gräsbeck syndrome; IRE, immunosuppressant-responsive enteropathy; LC/ MS-MS, liquid chromatography-tandem mass spectrometry; LoQ, lower limit of quantification; MMA, methylmalonic acid; NRE, nonresponsive enteropathy; PLE, proteinlosing enteropathy; RI, reference interval; SI, small intestine. egg, milk products as well as fish having high cobalamin content, but smaller amounts can also be produced by the intestinal microbiota. 1 Plants and plant products contain virtually no cobalamin and, whereas ruminants and other herbivores can produce a sufficient amount of cobalamin in their intestines, omnivorous or carnivorous animals including dogs and cats are not able to produce cobalamin.
The intestinal microbiota of dogs and cats can produce cobalamin in the presence of cobalt, but because this site of cobalamin production is distal to the site of its absorption, this ability appears to be of little benefit to the animal. Most commercial pet foods, including vegan or vegetarian diets, are supplemented with cobalamin, 2,3 but the content of dietary cobalamin varies between diets (dry diets: 0.05-0.25 mg/kg dry matter basis; canned diets: 0.03-0.59 mg/kg dry matter basis). 4 The National Research Council (NRC 2006 ) recommendation for cobalamin fortification is 35 μg/kg dry matter for canine diets, regardless of the canine life stage. 5 The concentration of serum cobalamin and cobalamin-dependent metabolites is not related to the dogs being fed a biologically appropriate raw food diet or a commercial dog food. 6 Bound to dietary protein, cobalamin reaches the stomach where it is released by activated pepsinogen and gastric acid. 7 Free cobalamin is then bound to haptocorrin (R protein, transcobalamin I) to protect it from bacterial utilization in the proximal GI tract. 7 In the duodenum, pancreatic proteases separate cobalamin from haptocorrin, and free cobalamin is bound to intrinsic factor (IF). The major site of IF synthesis is the gastric mucosa in humans, whereas in dogs IF is produced primarily by the exocrine pancreas and to a lesser extent in the stomach. 8, 9 The cobalamin-IF-complex is then absorbed by receptor-mediated endocytosis. The receptor, known as cubam, is localized at the brush border of the ileum (Fig. 1A and 2 ). This receptor complex is comprised of 2 subunits, the proteins amnionless (AMN) and cubilin (CUBN) ( Fig. 1A and 2 ). 10 In addition to receptormediated cobalamin uptake at the ileal brush border epithelium, approximately 1% of dietary cobalamin is absorbed via passive diffusion across the intestinal mucosal epithelium, assumed to occur along the entire length of the GI tract. 11 Within the lysosomes of the enterocytes, cobalamin is separated from IF and the receptor. Bound to another transport protein, transcobalamin, cobalamin is then transported within the bloodstream to its target tissues. In humans, 20%-30% of the cobalamin is bound to transcobalamin II, whereas most of the circulating cobalamin (70%-80%) is bound to transcobalamin I and thus unavailable for cellular uptake. 12, 13 Although transcobalamin II appears to be much more abundant in dogs than in humans, transcobalamin I exists in dogs. 14 At the target tissue, cobalamin enters the cells through specific receptors and is then released from transcobalamin II ( Fig. 1A) . 12 Approximately 15 μg/day of recirculating cobalamin is extracted by hepatocytes and secreted in bile bound to haptocorrin for enterohepatic recirculation. 15 Within all eukaryotic cells, cobalamin acts as an essential cofactor for the intracellular enzymes methionine synthase and methylmalonyl-CoA mutase ( Fig. 3 ). 16 F I G U R E 1 Schematic of the absorption of cobalamin by enterocytes in the distal small intestine (ileum). A, In the duodenum cobalamin is bound to intrinsic factor (IF). The cobalamin-IF complex is then absorbed by receptor-mediated endocytosis. This cubam receptor is localized at the brush border of the distal small intestine (ileum). The receptor complex is comprised of 2 subunits, the proteins amnionless (AMN) and cubilin (CUBN). Within the lysosomes of the enterocytes, cobalamin is separated from IF and the receptor. Bound to the transport protein transcobalamin II, cobalamin is then transported within the bloodstream to its target tissues. A small amount of circulating cobalamin is bound to transcobalamin I and thus unavailable for cellular uptake. Approximately 1% of dietary cobalamin is absorbed via passive diffusion across the intestinal mucosa. B, Various disorders can impair cobalamin metabolism 2.2 | Intracellular function
| Methionine synthase
Methionine synthase, a cobalamin-, folate-, and pyridoxine (vitamin F I G U R E 2 Immunofluorescent staining of the cobalamin receptor subunits in the canine ileum epithelium. The expression of the cobalamin receptor was detected immunohistochemically in a cross section of an ileal villus from a dog using antibodies for the subunits (A) amnionless (AMN, green) and (B) cubilin (CUBN, green). Both subunits are localized throughout the entire enterocyte (cell membrane and cytosol). Nuclei are stained in blue with diamidine phenylindole (DAPI). The insert shows the corresponding secondary antibody control. Images were acquired using equipment at the Laser Scanning Microscopy Core Facility (College of Veterinary Medicine, University of Leipzig, Germany) F I G U R E 3 Intracellular pathways of cobalamin metabolism. Methionine synthase catalyzes the regeneration of methionine from homocysteine. Disorders associated with a deficiency in cellular cobalamin availability thus can lead to functional folate deficiency and increased concentrations of homocysteine. Methylmalonic CoA mutase catalyzes the reaction from methylmalonyl CoA to succinyl CoA which is a key molecule in the tricarboxylic acid cycle. A lack of intracellular cobalamin leads to a reduced enzyme activity and an accumulation of methylmalonic acid (MMA). Excess MMA is excreted in the urine. MMA can also inhibit the activity of carbamoyl phosphate synthetase I, an enzyme of the urea cycle. Carbamoyl phosphate synthetase I normally metabolizes ammonia to carbamoyl phosphate. When this metabolic process is impaired, plasma ammonia concentration increases
| Methylmalonyl-CoA mutase
Methylmalonyl-CoA mutase, a cobalamin-dependent enzyme, catalyzes the formation of succinyl-CoA from methylmalonyl-CoA, which is produced by the catabolism of odd-chain fatty acids and amino acids ( Fig. 3 ). Succinyl-CoA is a key molecule in the citric acid cycle. A lack of intracellular cobalamin leads to a reduced enzyme activity and an accumulation of methylmalonic acid (MMA) intracellularly and subsequently also systemically (methylmalonic acidemia). On the one hand, excess MMA undergoes urinary excretion (methylmalonic aciduria); on the other hand, MMA can also inhibit the activity of carbamoyl phosphate synthetase I, an enzyme of the urea cycle. Carbamoyl phosphate synthetase I normally metabolizes ammonia to carbamoyl phosphate. When this metabolic process is impaired, plasma ammonia concentrations typically increase. 1, [17] [18] [19] [20] Neurological disorders can thus be a complication of cobalamin deficiency states in dogs due to the increase in systemic MMA concentrations. 1, 17, 18, 21 In humans, neurological symptoms also occur in organic acidemias including methylmalonic acidemia. 22 
| Excretion of cobalamin
Body stores of cobalamin in dogs far exceed the amount of cobalamin that is normally lost through the intestinal tract. Cobalamin undergoes biliary excretion (bound to haptocorrin), and a large amount of cobalamin is conserved by enterohepatic recirculation. 1 Renal glomerular filtration of the transcobalamin II-cobalamin complex is followed by tubular reabsorption to minimize urinary losses of cobalamin. Megalin, an endocytic receptor in the proximal renal tubulus that has a high affinity for the transcobalamin II-cobalamin complex, mediates renal reabsorption and retention of cobalamin. Free cobalamin is excreted in the urine. 23, 24 The cubam receptor is also present in the kidneys 25 and is involved in the renal reabsorption of several proteins (eg, albumin, transferrin, and vitamin D-binding protein). (Table 1 ). An immunoassay is also available for measurement of serum cobalamin concentrations in dogs but yields different results than the chemiluminescent assay. 29 The main indication for measuring serum cobalamin is to identify a subnormal cobalamin status. 30 Because cobalamin-dependent metabolic reactions are localized to the intracellular compartment (ie, cytoplasm and mitochondria), the serum cobalamin concentration does not necessarily exactly reflect the whole-body cobalamin status in an individual dog. Intracellular storage of cobalamin is mostly as a cofactor bound to cobalamin-dependent enzymes that might or might not be saturated with cobalamin. Decreased liver and kidney cobalamin stores, and certain defects in cobalamin metabolism, such as malabsorption due a defect in the ileal receptor, can result in cobalamin deficiency. Therefore, other markers that more closely reflect the intracellular availability of cobalamin such as the serum concentration of HCY and MMA should ideally be included when assessing cobalamin status. 31 Cobalamin is stable in serum even if samples are not strictly protected from light. 32 Thus, in clinical practice, measurement of serum cobalamin can be conveniently performed in serum samples that are archived for up to 5 days. However, the long-term (>5 days) stability of cobalamin in serum samples has not been reported. 5.9-31.9 μmol/L. 33 In human medicine, other methods that are used for measuring HCY are a chemiluminescent microparticle immunoassay and an enzyme-cycling assay (Homocysteine Cobas C, Integra, Roche).
| LABORATORY TESTING TO EVALUATE COBALAMIN STATUS
| Serum HCY concentration
Homocysteine is a sulfurated intermediate amino acid that is produced from dietary methionine and is then either remethylated to methionine or metabolized to cysteine. [34] [35] [36] Cobalamin (vitamin B 12 ), folic acid (vitamin B 9 ), and pyridoxine (vitamin B 6 ) are essential cofactors for enzymes involved in the metabolism of HCY. 37 Hyperhomocysteinemia thus reflects an insufficient intracellular availability of cobalamin, folic acid, or both for the synthesis of methionine, and HCY is a sensitive marker for the detection of intracellular B vitamin deficiency. 37, 38 Serum HCY concentrations increase early in the course of cobalamin deficiency, and hyperhomocysteinemia can contribute to the development of clinical signs caused by the decreased availability of cobalamin for cellular metabolism. 6 However, increased serum or plasma HCY concentrations are less specific for intracellular lack of cobalamin than is increased serum MMA concentrations. 39 Serum HCY concentrations can also be increased with renal insufficiency 40 or hypothyroidism. 41 In humans, HCY has direct toxic effects on neurons and endothelial cells, can induce DNA strand damage, oxidative stress, and apoptosis 36, 42 and also induce hepatic degeneration and fibrosis. 43 Even small changes in serum HCY concentrations (≥5-10 μmol/L) increase the risk of cardiovascular diseases in people. 36, 37 Increased serum HCY concentrations occur in dogs with cardiac or renal disease. 44 Circulating HCY is mostly bound to albumin. As a consequence, diseases associated with hypoalbuminemia, such as protein-losing enteropathy (PLE), might be associated with a lower degree of hyperhomocysteinemia than expected or even with normohomocysteinemia. 38, 45 However, it is likely that breed-specific effects exist. For example in Greyhounds, 38 Because MMA production increases as a result of decreased intracellular availability of cobalamin, MMA is a useful marker of cobalamin deficiency at the cellular level. Such a deficiency can occur due to cobalamin malabsorption, deficient cobalamin transport (which is not reported in dogs), depletion of cobalamin stores in the liver and kidneys secondary to cobalamin malabsorption, or a combination of these, leading to insufficient amounts of cobalamin entering the cells.
Tissues or cells with a high turnover rate such as enterocytes or blood cells are primarily affected. Dogs with a serum cobalamin concentration below RI have significantly higher serum MMA concentrations compared to dogs with normocobalaminemia, but serum MMA concentrations are increased in some (12%) normocobalaminemic dogs. 26 In cobalamin-deficient Shar-Peis, where a suspected hereditary but late-onset form of cobalamin deficiency with mostly signs of GI disease exists, serum MMA concentrations can even be 10 times higher than in cobalamin-deficient dogs of other breeds. 27 Careful interpretation of serum MMA concentrations should be exercised in the presence of other conditions that can affect serum MMA concentrations, such as renal insufficiency causing increased serum MMA concentrations. 48 Therefore, serum concentrations of creatinine, symmetric dimethylarginine, or both should also be evaluated when interpreting serum MMA concentrations. 49 Other possible causes for increased serum MMA concentrations, unrelated to primary cobalamin deficiency and renal disease, are dehydration, small intestinal (SI) dysbiosis, 26, 50 and inherited defects of the enzyme systems involved in the metabolism of cobalamin and MMA. Inherited etiologies also include defects in the absorption and transport of cobalamin such as a deficiency of transcobalamin II. Such defects have been reported in people, but further studies are needed to investigate whether dogs are also affected by these.
Of healthy normocobalaminemic Border Collies, 38% have increased urine MMA concentrations. 6 None of these dogs have increased serum HCY or decreased cobalamin concentrations compared to cobalamin-deficient dogs. These cobalamin-deficient Border
Collies have a primary methylmalonic aciduria. However, bacterial contamination of urine also has to be considered as a cause for increased urinary MMA concentrations. 47 A similar presentation occurs in children with a defect in the methylmalonyl-CoA mutase. 37, 51, 52 Urine MMA concentrations are also measured by GC/MS 26 or LC/MS-MS. 47 The RI was determined as 0-4.2 mmol/mol of creatinine in 1 report. 6 Dogs normally excrete <10 mg MMA/g of creatinine (<9.6 mmol MMA/mol of creatinine). 1 Normalizing urine MMA to creatinine concentration minimizes the concentration or dilution effect of urine on MMA concentrations. An advantage of measuring urinary MMA concentration is easier determination because MMA concentrations in urine are up to 40-fold higher than in serum. Furthermore, MMA is stable in urine, and sample collection is less invasive compared to the collection of blood samples. 6 
| Interpretation of cobalamin status
The currently recommended interpretation of the cobalamin status in dogs is summarized in Twelve percent of dogs with chronic enteropathy and a serum cobalamin concentration within the normal RI have an increased serum MMA concentration. 26 Twenty-two percent of dogs with cobalamin close to the lower end of the RI have increased serum MMA concentrations. 33 These data suggest that a subtle or mild subclinical intracellular cobalamin deficiency exists in these dogs. In humans with suboptimal cobalamin status, the response to cobalamin supplementation is a marked reduction in serum MMA concentration. 55 Dogs with serum cobalamin concentrations at the lower end of the RI have a normalization of serum MMA concentrations after cobalamin supplementation. 33 This could indicate that the discrepancy between an increased serum MMA and a normal cobalamin concentration reflects intracellular cobalamin deficiency despite that body stores of cobalamin are sufficient to maintain normocobalaminemia.
Such a "cobalamin resistance" occurs in geriatric, diabetic, and hemodialysis human patients. 53 Alternative explanations could be the shift to an increased pool of circulating cobalamin with hepatic disease 53 or a compromised translocation of cobalamin to the intracellular space (which is not reported in dogs).
| Hypocobalaminemia
Hypocobalaminemia is typically referred to in dogs with a serum cobalamin concentration between the lower limit of quantification (LoQ) of the assay and the lower reference limit ( Fig. 4 ). However, careful interpretation is necessary because different laboratories use different LoQs (Table 1) .
Thirty-one percent of hypocobalaminemic dogs (as defined above)
have serum MMA concentrations above the RI, 26 and these dogs are assumed to be cobalamin-deficient on the cellular level. However, it is After supplementation, cobalamin is rapidly extracted from plasma by tissues where it binds to cobalamin-dependent enzymes with a relatively long half-life. 58 Thus, it is possible that the half-life of cobalamin that is bound intracellularly as a coenzyme exceeds the residence time of cobalamin within the circulation, which would mean that cobalamin continues to be active in the tissues and cobalamindependent metabolic processes are able to occur despite low serum cobalamin concentrations. This is often observed in the treatment of dogs with inherited disorders of cobalamin metabolism. 59 
| Cobalamin deficiency
The term cobalamin deficiency is not well-defined in the veterinary literature. Most current cobalamin assays have an LoQ between 45 and 150 ng/L ( Table 1) . We propose using the term cobalamin deficiency for dogs with an undetectable serum cobalamin concentration and a serum MMA concentration above RI (Table 2, Figure 4 ).
Sixty-three percent of dogs with undetectable serum cobalamin concentrations have increased serum MMA concentrations indicating cellular cobalamin deficiency. 26 Normal serum MMA concentrations in the remaining 37% of dogs with an undetectable serum cobalamin concentration might suggest that a sufficient amount of cobalamin as a cofactor is bound to cobalamin-dependent enzymes and a normal activity of these enzyme is maintained in these dogs, whereas cobalamin concentrations in the circulation are already severely decreased because of their much shorter half-life. 58 Therefore, measurement of serum cobalamin concentration alone is not sufficient to diagnose or exclude intracellular cobalamin deficiency, and determination of serum MMA (and HCY) is recommended in addition to serum cobalamin concentration.
| Hypercobalaminemia
Hypercobalaminemia refers to a serum cobalamin concentration above the normal RI. Until recently, hypercobalaminemia was considered as a benign finding and was basically ignored in companion animals. However, recent data in people suggest that hypercobalaminemia is an underestimated finding that can reflect a number of serious underlying diseases such as solid neoplasms, hematological and other malignancies, and hepatic or renal diseases. [60] [61] [62] Abnormally high serum cobalamin concentrations occur in cats with hepatic and neoplastic diseases. 63 A retrospective analysis of the medical records and data from 592 dogs that were presented for further diagnostic workup at the University of Leipzig Small Animal Clinic showed that 2% (n = 11) of all dogs in which serum cobalamin status was determined and that did not receive any supplemental cobalamin (n=487 dogs) had a serum cobalamin concentration above RI, ranging from 1,100-3,561 ng/L (median: 1,334 ng/L) (unpublished data).
These hypercobalaminemic dogs had mostly (73%) signs of chronic GI disease, and a neoplastic condition could not be definitively excluded in 82% of the dogs. These findings suggest that hypercobalaminemia is less frequently observed in dogs than in cats, 63 in which a prevalence of 14% (28 of 202 cats) was observed in the study above diagnosed as the acquisition and analysis of the SI microbiota is cumbersome and invasive), and inherited conditions (Fig. 1B) . 49, [64] [65] [66] [67] [68] [69] [70] [71] Hypocobalaminemia also occurs in people with IBD (Crohn's disease and ulcerative colitis). There are no reported cases of cobalamin deficiency of dietary origin in dogs. 31 
| Clinicopathological findings and clinical presentation
Blood cell count abnormalities, typically nonregenerative anemia with megaloblastosis, neutropenia, and hypersegmented neutrophils, can be early signs of derangements in cobalamin metabolism. 72 With progression, disorders of phospholipid and amino acid metabolism have been documented in other species and might also occur in dogs. 21, 73 In addition to blood cell dyscrasias and organic acidemias associated with neurological signs, especially dogs with hereditary cobalamin deficiency can show severe clinical signs such as failure to thrive, anorexia, lethargy, vomiting, and diarrhea. The age of affected dogs at presentation with clinically apparent disease also varies, with the majority of dogs showing clinical signs early in life and a smaller proportion of dogs having a more delayed onset of clinical signs.
| Hereditary conditions
A genetic background for cobalamin deficiency has been confirmed or suspected in Giant Schnauzers, 1, 74 
| Breed predispositions for hypocobalaminemia and cobalamin deficiency
Serum concentrations of cobalamin have been used for many years in veterinary practice to identify dogs with hypocobalaminemia or cobalamin deficiency, and 2 large surveys have been conducted with the aim to identify canine breeds that might have a predisposition to develop cobalamin deficiency. 70, 84 Test results of serum samples from 9,960 dogs submitted over a 13-year period to a laboratory in the United Kingdom were analyzed to determine breed predispositions for hypocobalaminemia, hypofolatemia, or both. 84 In the North American study, 70 serum cobalamin test results from 28,675 dogs of 164 breeds were reviewed to identify breeds with an increased risk of being identified with hypocobalaminemia. This study found Greyhounds to have the highest proportion of serum samples submitted for cobalamin analysis and also the lowest serum cobalamin concentrations compared to the other 18 breeds of dogs that were significantly more likely to have a subnormal serum cobalamin concentration. This suggests that hypocobalaminemia or cobalamin deficiency occurs frequently in this breed, which is supported by another study indicating that Greyhounds frequently have hypofolatemia with or without hypocobalaminemia. 38 The high percentage of affected dogs with hyperhomocysteinemia in this study suggests that cobalamin deficiency is common in this breed. 38 However, it is also possible that normal serum cobalamin concentrations in Greyhounds are lower than in dogs of other breeds, thus calling for a breed-specific RI. An effect of exercise is unlikely because Greyhounds included in the study were all retired racing dogs. 38 
| Selective cobalamin malabsorption
Selective cobalamin malabsorption is a rare congenital disease. The first report about selective cobalamin malabsorption in dogs describes 2 related Giant Schnauzers that lacked the expression of the cobalamin-IF-receptor complex in the apical brush border of the ileal and renal epithelium. 1 The human analog of this rare genetic disorder is called Imerslund-Gräsbeck syndrome (IGS). Dogs with IGS are unable to absorb dietary cobalamin. 1, 17, 74 Classical clinical signs of IGS such as intermittent diarrhea, inappetence, poor body condition, and failure to grow typically manifest within the first year of age. Around that time fetal stores of cobalamin are depleted while growth demands cobalamin to be utilized at high rates. Dogs might be misdiagnosed because of the secondary effects of hypocobalaminemia on metabolism such as the development of hypoglycemia, ketoacidosis, and hyperammonemia. 18, 19, 78 Therefore, cobalamin deficiency should be considered as a differential diagnosis in dogs presented with a suspicion of a portosystemic shunt, hydrocephalus, or metabolic disorders such as hypoglycemia and renal insufficiency. 17 Another possible clinical manifestation of IGS is intermittent impaired swallowing. 76 Mucosal ulcerations might also develop, 76, 85 but glossitis, glossodynia, and stomatodynia are reported only in people with cobalamin deficiency. Additionally, bradyarrhythmia is a possible clinical sign in dogs. 76 Skin lesions (reversible hyperpigmentation) occur in children with IGS. 86 Hematologic abnormalities in human patients with IGS include a dyshematopoesis that is typically characterized by a nonregenerative anemia of varying severity and neutropenia. Microscopically, hypersegmented neutrophils may be noted. Megaloblastosis is rarely seen in dogs, 75 and some dogs with IGS present with a normal hemogram. 76 Although children with this disorder develop macrocytic anemia, the anemia in dogs is usually normocytic and normochromic. 72, [87] [88] [89] Thus, megaloblastic anemia does not appear to be as closely associated with cobalamin deficiency in dogs as it is in people. In affected dogs, both large and small red blood cells are present systemically, resulting in an increased red cell distribution width while the mean cellular volume remains within RI. 72 Rarely, dogs with IGS can present with Heinz body anemia caused by hyperhomocysteinemia. 78 Breed-specific changes in serum cobalamin concentrations and distinct clinical manifestations exist in the Border Collie, Beagle, and Chinese Shar-Pei breeds (Table S1 ).
Border Collie
Several case reports and case series have described a selective cobalamin malabsorption in the Border Collie breed. 18, 75, 76, 78 Clinical manifestations in some cases are mild and the onset of clinical signs can be delayed into early adulthood compared to other breeds with selective cobalamin malabsorption. 17, 75 Also, juvenile cobalamin deficiency might not be routinely associated with hematologic changes in the Border Collie breed. 18, 75, 76 About 40% of healthy Border Collies have increased urine MMA levels, 6 but none of the normocobalaminemic dogs in that study had increased plasma HCY concentrations compared to the Border Collies with cobalamin deficiency. It has been hypothesized that these dogs have a primary methylmalonic aciduria. 6 Of note, hypocobalaminemia is also associated with an increased prevalence of EPI in Border Collies. 70 
Beagle
Hereditary cobalamin malabsorption is reported in Beagle dogs, 17, 59, 85, 90 and 2 Beagles with selective cobalamin malabsorption developed degenerative liver disease. 83 The hepatopathies seen in these dogs might be associated with the chronic hyperhomocysteinemia which was demonstrated to promote hepatic inflammation and fibrosis in an experimental study in rats. 43 Degenerative hepatopathies are also well described in farm animals, especially in lambs and goats with decreased cobalt intake causing hypocobalaminemia, but this etiology has not been reported in dogs with hereditary cobalamin malabsorption. 83 Decreased phagocytic activity has been demonstrated in human patients with cobalamin deficiency. 91 Cobalamin-deficient Beagle dogs are suspected to be immunosuppressed, supporting the development of complicating infections such as fungal hepatopathy or necrotizing pneumonia. 78, 81, 92 Chinese Shar-Pei
Chinese Shar-Peis have a high prevalence of cobalamin deficiency compared to other canine breeds. 27, 79, 80, 93 Even apparently healthy Chinese Shar-Peis have increased serum MMA concentrations compared to healthy dogs of other breeds, which led to the hypothesis that some healthy Chinese Shar-Peis have subclinical cobalamin deficiency. 80 Cobalamin deficiency in Chinese Shar-Peis is also associated with hyperhomocysteinemia. 27 Clinical signs of affected dogs reflect primarily an involvement of the GI tract with chronic signs of GI disease such as diarrhea, vomiting, and weight loss. 93 Classical signs of cobalamin deficiency such as hyperammonemia, hypoglycemia, and seizures are typically lacking in these dogs. 79 Hypocobalaminemia in Chinese Shar-Peis is not associated with other common diseases in this breed such as cutaneous mucinosis or Shar-Pei fever. 93 However, evaluation of several biomarkers of inflammation suggests the existence of an inflammatory phenotype in both hypocobalaminemic and normocobalaminemic Chinese Shar-Peis. 93 This might reflect compromised GI health in affected dogs, with the result of a low-grade inflammation and malabsorption of vitamins such as cobalamin.
Komondor
A recent study reported that selective cobalamin malabsorption is also inherited via an autosomal recessive trait in Komondor dogs, an old Hungarian herding dog breed. 94 
| Genetic causes of selective cobalamin malabsorption
Each of the 2 subunits of the cubam receptor complex (ie, AMN and CUBN) depends on the normal structure of the other part of the receptor for epithelial brush border expression and function. 81 81 Furthermore, in a study including 200 randomly selected Border Collies, the frequency of dogs being heterozygous for the CUBN mutation was relatively low at 6.2%, 77 whereas increased carrier frequency has been noted in Beagles, but the disease occurrence might be geographically dependent. 82, 90 In Komondor dogs, a CUBN splice-site variant causes cobalamin deficiency. 94 Genetic tests have become commercially available and allow for a diagnosis prior to the clinical manifestation of the condition and also the detection of asymptomatic carriers to guide breeding decisions (centerofanimalgenetics.com, animalabs.com, or www.laboklin.de). A large genomic study in Chinese Shar-Peis revealed an association of 2 canine microsatellite markers, located on canine chromosome 13, with cobalamin deficiency in this breed. 79 However, there are no previously identified genes in this chromosomal region that are associated with cobalamin deficiency in dogs or other species. 79 
| Gastrointestinal diseases
| Exocrine pancreatic insufficiency
Cobalamin deficiency is common in dogs with EPI. A study showed 82% of dogs with EPI have decreased serum cobalamin concentrations, and 36% of these dogs had severe hypocobalaminemia (defined as a serum cobalamin concentration of <100 ng/L in this study). 66 A breed predisposition for EPI exists in German Shepherd Dogs, Rough Coated Collies, Chow-Chows, Cavalier King Charles Spaniels, and
West Highland White Terriers, with German Shepherd Dogs representing about 60% of all cases of EPI. 66 Pancreatic acinar atrophy is also an inherited disorder in the Eurasian breed. 96 Exocrine pancreatic insufficiency is characterized by an inadequate production of digestive enzymes from pancreatic acinar cells, leading to the typical clinical signs of weight loss in the face of polyphagia and increased fecal volume. 97, 98 Failure to absorb cobalamin in dogs with EPI might be caused by 4 postulated or hypothetical mechanisms: pancreatic secretion of IF is reduced or absent, digestive enzymes are lacking causing an impaired release of cobalamin from haptocorrin and thus no binding of cobalamin to IF, secondary SI dysbiosis compromising the endogenous production of cobalamin, and the intestinal mucosa might also be compromised by the presence of toxic metabolites due to SI dysbiosis. 9,99-101 However, in people cobalamin assimilation does not improve with antibiotic treatment, 102 and there is no data that demonstrate a benefit of probiotics (eg, Enterococcus faecium SF68 103 ) or prebiotics.
Because the exocrine pancreas is the major site of IF synthesis in dogs, cobalamin supplementation is often necessary in these dogs.
However, cobalamin deficiency in some cases is not corrected by enzyme replacement alone likely because IF is not consistently a component of the exogenous enzyme mixture. 99 Treatment with bovine pancreatic enzyme extract is also not sufficient to restore cobalamin absorption in dogs with EPI, because IF appears to be species-specific.
The fact that serum cobalamin concentrations <100 ng/L are a negative prognostic factor 66 underlines the importance to adequately supplement dogs with EPI, but only 4 of 135 (3%) hypocobalaminemic dogs with EPI were given supplemental cobalamin in that study. 66 Another recent study revealed a prevalence of hypocobalaminemia (serum cobalamin concentration <350 ng/L) of 55% in dogs with EPI. 104 Hypocobalaminemia was also shown to be a negative prognostic factor in that study, and 112 of 116 dogs (82%) received cobalamin supplementation. 104 (such as vomiting, diarrhea, weight loss, or a combination of those) for longer than 3 weeks and are diagnosed retrospectively based on the response to treatment. 65, 71 It has been postulated that chronic mucosal disease affecting the ileum reduces the epithelial expression or function of the cubam receptor leading to a reduced mucosal uptake of cobalamin. However, currently there are no studies that have investigated the expression levels of the ileal cobalamin-IF-receptor in dogs with chronic enteropathies.
| Chronic inflammatory enteropathies
In addition, cobalamin has been hypothesized to be decreased in dogs with CIE because of secondary SI dysbiosis. Once the body stores of cobalamin are depleted, cobalamin deficiency can occur. 105 The half-life of cobalamin in healthy dogs is approximately 6-16 weeks. 106 It is assumed that this half-life is decreased in dogs with CIE as a result of a reduced cobalamin absorption in the face of normal biliary excretion and enterohepatic circulation. 49 Reported prevalences of hypocobalaminemia in dogs with CIE ranged from 19% to 38%, 49, 65, [107] [108] [109] [110] and similar findings have been reported in cats. 111 Dogs with suboptimal serum cobalamin status might not respond to treatment of the primary disease process unless given supplemental cobalamin, because cobalamin is essential for many cell functions and mucosal regeneration, and a deficiency can contribute to mucosal inflammatory infiltration and villous atrophy. 72, 105 Correlation of hypocobalaminemia with histopathologic findings ). [112] [113] [114] Because histological lesions of CIE might be found in the ileum in the face of a normal duodenal mucosa, ileal biopsies should be routinely collected in addition to duodenal biopsies in all dogs with chronic signs of GI disease undergoing GI endoscopy. 113, 114 Hypocobalaminemia correlates with an increased number of intraepithelial lymphocytes in the ileal mucosa, 114 presenting evidence of an association between ileal mucosal inflammatory changes and hypocobalaminemia in dogs with CIE. However, the expression of the cobalamin-receptor in dogs with CIE has not been evaluated.
Correlation of hypocobalaminemia with outcome in dogs
Several factors have been evaluated for their potential to predict outcome in dogs with CIE. 65 In addition to the presence of severe mucosal lesions in the duodenum and hypoalbuminemia (serum albumin concentration of <20 g/L), hypocobalaminemia (defined as a serum cobalamin concentration of <200 ng/L in this study) at the time of diagnosis might predict refractoriness to treatment and was strongly correlated with a negative outcome despite supplementation of cobalamin for 6 weeks. 65 However, despite that hypocobalaminemia is a negative prognostic factor, adequate supplementation of cobalamin appears to be essential for the success of treatment. Thus, further studies need to investigate if early initiation of cobalamin supplementation is associated with a better outcome in dogs with CIE.
Hypocobalaminemia also correlates with hypoalbuminemia in dogs with CIE. 65, 108, 109 Protein-losing enteropathy
Protein-losing enteropathy is a syndrome associated with an abnormal loss of albumin into the intestinal lumen. 69 Prevalences of hypocobalaminemia range from 43%-75% in dogs with non-neoplastic, noninfectious causes of PLE. 65, 107, 124 Hypocobalaminemia was also associated with decreased serum alpha 1 -proteinase inhibitor concentrations (presumably due to PLE) in Yorkshire Terriers. 125 Serum cobalamin concentrations should be evaluated in all dogs with PLE and, if needed, supplemental cobalamin be started early. 69 
| Alimentary lymphoma
Sixteen percent of dogs with multicentric lymphoma have hypocobalaminemia, and this finding is associated with a poor outcome. 68 A higher rate of hypocobalaminemia (40% and 71%) is seen in dogs with low-grade (lymphocytic) GI lymphoma. 126, 127 It is presumed that the hypocobalaminemia in dogs with lymphoma is a consequence of the ileal infiltration with neoplastic lymphocytes hypothetically resulting in a disruption of the receptor-mediated GI uptake of cobalamin. 68 
| Small intestinal dysbiosis
Small intestinal (SI) dysbiosis is defined as an altered composition, richness, or both of the intestinal microbiota. 50 Competition between bacteria and host cells for essential nutrients such as cobalamin can lead to malnutrition. 67 
| TREATMENT
Cobalamin should be supplemented whenever serum cobalamin concentration is subnormal. There is a 12% probability that CIE dogs with low-normal serum cobalamin concentration (ie, less than approximately 400 ng/L) might also benefit from supplementation. 26, 33 Cyanocobalamin has traditionally been used for supplementation, as it is widely available and inexpensive. The possibility of normocobalaminemia being restored in hypocobalaminemic dogs with CIE when treating the underlying disease without supplementing cobalamin has not been demonstrated.
In dogs with CIE and suboptimal cobalamin status, cobalamin is recommended to be given at a dose of 50 μg/kg SC every 7 days or 50 μg/kg PO q24h. 28, 33 Current consensus is that oversupplementation with cobalamin or cobalamin toxicity does not occur.
While this is a reasonable assumption based on theoretical considerations, there are no data available in companion animals to support this hypothesis. In people, chronic oversupplementation with cobalamin might increase the risk for lung cancer in smokers. 129, 130 
| Monitoring
If the underlying disease process has resolved and cobalamin body stores have been restored, serum cobalamin concentration should be above the RI at the time of retesting. If serum cobalamin concentration is still within RI (ie, supranormal serum cobalamin concentrations have not been achieved), cobalamin supplementation was traditionally recommended to be continued every 2-4 weeks. More than 90% of dogs with a suboptimal serum cobalamin status achieve hypercobalaminemia within 4 weeks of parenteral cobalamin supplementation, but serum cobalamin concentrations decreased within the RI towards the 12-week mark of cobalamin supplementation in the majority of these dogs. 28 In some dogs, serum cobalamin concentrations are not adequate with cyanocobalamin supplementation, and hydroxocobalamin might be more effective in these dogs (Steiner JM, personal communication). However, monitoring serum MMA concentrations alone or in combination with serum cobalamin concentrations might be a more appropriate way to reevaluate the canine cobalamin status after treatment. 59 A study investigating the effect of injectable hydroxocobalamin for the treatment of Beagle dogs with IGS showed a dose of 1 mg hydroxocobalamin administered IM to be adequate for maintaining a normal clinical status and normal urine MMA concentrations for up to 2 months. 59 Hydroxocobalamin is considered the treatment of choice for children with IGS 88, 133, 134 and other types of hereditary cobalamin deficiency. 135, 136 It is likely more effective than cyanocobalamin because this compound presents the natural form of cobalamin. 137 In addition, IM injections of hydroxocobalamin appear to cause less pain than cyanocobalamin. 134 5.2 | Oral cobalamin supplementation
| Protocol
Cobalamin (50 μg/kg PO) is administered once daily (250-1000 μg in dogs, depending on the size of the dog; see Table S3 ) over a period of 12 weeks, 33 followed by a recheck of serum cobalamin concentration after discontinuation of supplementation. Dogs were rechecked the day after the last PO cobalamin dose in this study, 33 but the authors typically recheck serum cobalamin concentration 1 week after the last cobalamin tablet.
| Monitoring
Several studies in human patients with hypocobalaminemia suggest that supplementation with oral cobalamin might be as effective as parenteral administration. [138] [139] [140] A study that included 51 dogs showed that serum cobalamin concentrations increased significantly and normocobalaminemia was achieved in all hypocobalaminemic dogs with chronic enteropathy after daily oral cobalamin supplementation for at least 3 weeks (20-202 days). 141 However, similar to this study, another investigation by the same research group showed that supranormal serum cobalamin concentrations were achieved in only about half of the dogs. The dogs in this study reached normal serum cobalamin concentrations within 4 weeks of receiving PO cobalamin, but a hypercobalaminemic state was reached after 12 weeks of PO cobalamin supplementation in about two thirds of these dogs. 28 In addition, other recent studies suggest that daily PO cobalamin supplementation is effective to normalize the serum cobalamin status in dogs with CIE and also to maintain normal cobalamin status in dogs with hereditary cobalamin malabsorption that had previously been supplemented with parenteral hydroxocobalamin. 28, 47 Thus, oral cobalamin supplementation is a simple, noninvasive, and pain-free alternative to weekly SC injections of either cyanocobalamin or hydroxocobalamin. 28, 33 An alternative pathway of intestinal cobalamin absorption beyond receptor-mediated transport in the ileum is a possible explanation why oral cobalamin supplementation might be effective in spite of a defective receptor-mediated uptake into enterocytes.
This has also been reported in people. 11 However, expression levels of the ileal cobalamin-IF receptor in dogs with chronic enteropathies have not been investigated. 
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